Under Atmanirbhar Bharat 3.0 Mission COVID Suraksha was announced by the Government of India, to accelerate the development and production of Indigenous COVID Vaccines.
This is being implemented by Department of Biotechnology, Govt of India at Biotechnology Industry Resaerch Assistance Council (BIRAC), New Delhi.
To augument the capacity of Ingenious production Covaxin under the Mission the Department of Biotechnology, Govt of India in April 2021 provided financial support as Grant to vaccine manufacturing facilities for enhanced production capacities, which is expected to reach more than 10 crore doses per month by Sep 2021.
As a part of this augmentation plan, capacities of Bharat Biotech Limited, Hyderabad as well as other public sector manufactures are being upgraded with required infrastructure and technology. Financial support is being provided as grant from GoI to the tune of appx Rs 65 Cr to Bharat Biotech’s new Bangalore facility which is being repurposed to increase the capacity of vaccine production.
The following three public sector companies are also being supported to increase the capacity of vaccine production. 1. Haffkine Biopharmaceutical Corporation Ltd, Mumbai-a State PSE under State Govt of Maharashtra. Financial support of Rs. 65 crores as grant from GoI is being provided for this facility to make it ready for manufacturing.
The facility will have a capacity of 20 million doses per month, once functional. 2. Indian Immunologicals Limited (IIL), Hyderabad –A facility under National Dairy Development Board is being provided a grant of Rs. 60 crore and 3. Bharat Immunologicals and Biologicals Limited (BIBCOL), Bulandshahr a CPSE under Department of Biotechnology, Govt of India is being supported with a grant of Rs. 30 crores to prepare their facility to provide 10-15 million doses per month.
Further, Gujarat Biotechnology Research Centre, Department of Science and Technology Govt of Gujarat along with Hester Biosciences and OmniBRx has also firmed up its discussions with Bharat Biotech to scale up the COVAXIN technology and to produce minimum 20 million doses per month. Technology transfer agreement have been finalized with all manufacturers.